Cite
Latent Expression of the Epstein-Barr Virus (EBV)-Encoded Major Histocompatibility Complex Class I TAP Inhibitor, BNLF2a, in EBV-Positive Gastric Carcinomas.
MLA
Strong, Michael J., et al. “Latent Expression of the Epstein-Barr Virus (EBV)-Encoded Major Histocompatibility Complex Class I TAP Inhibitor, BNLF2a, in EBV-Positive Gastric Carcinomas.” Journal of Virology, vol. 89, no. 20, Oct. 2015, pp. 10110–14. EBSCOhost, https://doi.org/10.1128/JVI.01110-15.
APA
Strong, M. J., Laskow, T., Nakhoul, H., Blanchard, E., Yaozhong Liu, Xia Wang, Baddoo, M., Zhen Lin, Qinyan Yin, & Flemington, E. K. (2015). Latent Expression of the Epstein-Barr Virus (EBV)-Encoded Major Histocompatibility Complex Class I TAP Inhibitor, BNLF2a, in EBV-Positive Gastric Carcinomas. Journal of Virology, 89(20), 10110–10114. https://doi.org/10.1128/JVI.01110-15
Chicago
Strong, Michael J., Thomas Laskow, Hani Nakhoul, Eugene Blanchard, Yaozhong Liu, Xia Wang, Melody Baddoo, Zhen Lin, Qinyan Yin, and Erik K. Flemington. 2015. “Latent Expression of the Epstein-Barr Virus (EBV)-Encoded Major Histocompatibility Complex Class I TAP Inhibitor, BNLF2a, in EBV-Positive Gastric Carcinomas.” Journal of Virology 89 (20): 10110–14. doi:10.1128/JVI.01110-15.